Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Market Closed - Nasdaq Other stock markets 04:00:00 2024-04-30 pm EDT			5-day change	1st Jan Change
0.1227 ^USD	-20.07%		-38.65%	-85.56%

Apr. 22	Sector Update: Health Care Stocks Advance Premarket Monday	MT
Apr. 22	Sector Update: Health Care	MT

Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

March 27, 2024 at 04:19 pm EDT

Vaxxinity, Inc. reported earnings results for the full year ended December 31, 2023. For the full year, the company reported net loss was USD 56.93 million compared to USD 75.22 million a year ago. Basic loss per share from continuing operations was USD 0.45 compared to USD 0.6 a year ago.

Latest news about Vaxxinity, Inc.

Sector Update: Health Care Stocks Advance Premarket Monday	Apr. 22	MT
Sector Update: Health Care	Apr. 22	MT
Vaxxinity to Voluntarily Delist From Nasdaq; Shares Sink After Hours	Apr. 19	MT
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023	Mar. 27	CI
North American Morning Briefing : Tech in Focus on -2-	Mar. 25	DJ
Vaxxinity Announces Positive Target Engagement Data from Phase 1 Clinical Trial for Parkinson?s Disease at AD/PD? 2024	Mar. 07	CI
Vaxxinity, Inc. Announces the Publication of Data from Multiple Non-Human Primate Studies	Feb. 15	CI
Vaxxinity, Inc. to Present Data from UB-312 Program in Parkinson's Disease at International Conference on Alzheimer's and Parkinson's Diseases and Related Neurolog Disorders	Feb. 13	CI
Vaxxinity Announces Research Collaboration on Active Immunotherapies for Neurodegenerative Diseases with University of Florida	Jan. 30	CI
Vaxxinity Announces Collaboration on Space Medicine Research with University of Central Florida	Jan. 18	CI
Vaxxinity, Inc. Announces Resignation of Katherine Eade from the Board of Directors	Dec. 01	CI
Researchers return to Alzheimer's vaccines, buoyed by recent drug success	Nov. 20	RE
Vaxxinity, Inc. Reports Earnings Results for the Third Quarter and Nine Months Ended September 30, 2023	Nov. 08	CI
Vaxxinity, Inc. Announces Executive Changes	23-09-28	CI
Vaxxinity, Inc.(NasdaqGM:VAXX) added to S&P Global BMI Index	23-09-18	CI
Baird Starts Vaxxinity With Outperform Rating, Price Target is $7	23-09-08	MT
Vaxxinity, Inc. Announces Publication of UB-311 Safety, Tolerability, Immunogenicity, and Clinical Efficacy Data from Phase 2a Trial in Alzheimer's Disease	23-08-10	CI
Vaxxinity, Inc. Reports Earnings Results for the Second Quarter and Six Months Ended June 30, 2023	23-08-09	CI
Vaxxinity, Inc. Announces Executive Changes	23-07-27	CI
Vaxxinity Says B-312 Phase 1 Trial Shows Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients; Shares Rise	23-07-17	MT
Vaxxinity, Inc. Demonstrates Target Engagement of Toxic Alpha-Synuclein in Parkinson's Patients	23-07-17	CI
Vaxxinity Reports 'Positive' Results in Early-Stage Parkinson's Disease Trial	23-06-22	MT
Vaxxinity Announces UB-312 Successfully Met Primary Objectives of Phase 1 Clinical Trial in Parkinson's Disease	23-06-22	CI
Vaxxinity, Inc. Reports Earnings Results for the First Quarter Ended March 31, 2023	23-05-09	CI
Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2022	23-03-27	CI

Chart Vaxxinity, Inc.

Duration

Period

More charts

Company Profile

Vaxxinity, Inc. is a biotechnology company. The Company is engaged in the development of rationally designed prophylactic and therapeutic vaccines to combat common chronic disorders and infectious diseases with large patient populations and unmet medical needs. Its synthetic peptide-based Active Immunotherapy Medicines Platform (AIM Platform, formerly called the Vaxxine Platform) has the potential to enable a new class of medicines. Its pipeline consists of five lead programs focused on chronic disease, particularly neurodegenerative disorders, in addition to other neurology and cardiovascular indications. Its pipeline includes UB-311, UB-312, VXX-301, VXX-401 and UB-313. It also has developed an infectious disease product candidate, UB-612, as a heterologous booster against COVID-19. Its UB-311, which targets the primary pathological process of Alzheimerâs disease (AD) and UB-312, which targets the pathological process of Parkinsonâs disease (PD) and other so-called synucleinopathies.

Sector

Biotechnology & Medical Research

Calendar

2024-05-06 - Q1 2024 Earnings Release (Projected)

Related indices

Russell 2000

More about the company

	1st Jan change	Capi.
VAXXINITY, INC.	-85.56%	15.55M
IQVIA HOLDINGS INC.	+0.17%	42.19B
MODERNA, INC.	+10.92%	42.24B
LONZA GROUP AG	+44.30%	40.15B
CELLTRION, INC.	-6.20%	28.31B
ICON PUBLIC LIMITED COMPANY	+5.23%	24.63B
ALNYLAM PHARMACEUTICALS, INC.	-24.79%	18.2B
MEDPACE HOLDINGS, INC.	+26.69%	12.01B
CHARLES RIVER LABORATORIES INTERNATIONAL, INC.	-3.13%	11.76B
UNITED THERAPEUTICS CORPORATION	+6.57%	10.4B

Other Biotechnology & Medical Research

Vaxxinity, Inc.

Equities

VAXX

US92244V1044

Biotechnology & Medical Research

Vaxxinity, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023

Latest news about Vaxxinity, Inc.

Chart Vaxxinity, Inc.

Company Profile

Income Statement Evolution

Quarterly earnings - Rate of surprise

Sector Other Biotechnology & Medical Research